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Objective: To determine whether the newer fluoroquinolone antibiotics such as trovafloxacin posses enhanced activity 
against Gram-positive organisms, including Streptococcus pneumoniae, because the clinical activity of older quinolones 
against pneumococci has been questioned. 
Methods: In this study, the bactericidal activities of ciprofloxacin and trovafloxacin against six strains of penicillin- 
resistant and -sensitive strains of Streptococcus pneumoniae were compared using an in  vitro model that simutates 
human pharmacokinetics. Ciprofloxacin was administered at 750 rng every 12 h, higher than the usual daily dose of 
500 mg  twice a day. Trovafloxacin was administered at 300 mg  every 24 h for the six strains and at 200 mg  every 24 h 
for three of the strains. 
Results: The single 300-mg dose of trovafloxacin killed five of the six strains in  4 h, with no bacterial regrowth. 
Ciprofloxacin reduced the initial inoculum by 3-5 logs by 24 h. Although the 300-mg dose of trovafloxacin more rapidly 
eradicated susceptible strains, the activity of trovafloxacin at 200 m g  every 24 h was similar to that of ciprofloxacin at 
750 mg  every 12 h against the three strains tested. 
Conclusion: Trovafloxacin (and ciprofloxacin at high doses) eradicates susceptible strains of pneumococci in an in  vitro 
dynamic model. 
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INTRODUCTION 
Over the past several years, penicillin-resistant pneumo- 
cocci (PRP) have been isolated from infected patients 
with increasing frequency [ 11. These organisms are 
often resistant to macrolides, azalides and some cephalo- 
sporins [?I. Trovafloxacin is a new fluoronaphthyridone 
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with a long elimination half-life and enhanced activity 
against Gram-positive cocci, including Staphylococcus 
uureus, Streptococcus pyogenes, and both penicillin-suscep- 
tible and -resistant strains of Streptococcus pneurnoriiae [3]. 
In this study, the pharmacodynamics of trova- 
floxacin were compared to those of ciprofloxacin using 
an in vitro dynamic model of infection. This model 
simulates human pharmacokinetics and exposes bacteria 
to changing concentrations of antibiotic that mimic the 
human pharmacology of the drug. With a half-life of 
10-12 h, trovafloxacin can be administered orally once 
a day and results in a C,,,,, of 2.2 mg/L at a 200-mg 
dose and 3.3 mg/L at 300 mg. The usual dose of 
ciprofloxacin is 500 mg every 12 h, but it was studied 
here at the higher dose of 750 mg every 12 h [4]. 
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Table 1 Ciprofloxacin, trovafloxacin, penicillin and erythromycin susceptibility of the tested strains 
Ciprofloxacin Trovafloxacin Penicillin Erythromycin 
Strain MIC/MBC (mg/L) MIC/MBC (mg/L) MIC/MBC (mg/L) MICIMBC (mg/L) 
Streptococcus pueumoniae 31 90 1 .0/ 1 .o 0.125/0.25 2.0/’7.0 (R) 64/128 (R) 
Sfreptococcus pneurnoniac 5056A 1.0/2.0 0.125/0.25 8/8 (R) 6-1/13 (K) 
Streptococcus pneumonide 669 1 1.0/2.0 0.125/0.25 7.W1 (R) 0.06/0.125 (S) 
Strtpcorcus pneumoiiiae 2309A 1.0/2.0 0.125/0.25 8/8 (R) 0.06/0.115 (S) 
Strrptococrus przeurnotiiae 18032 32/64 1.0/2.O 0.03/0.03 (S) 0.03/0.06 (S) 
R, resistant; S. susceptible. 
Sfreptococcus ptieumoniae 9741 1.0/1 .o 0.125/0.25 0.015/O.015 (S) 0.03/0.06 (S) 
MATERIALS AND METHODS 
Six strains of pneumococci (Table 1) were selected from 
clinical isolates (courtesy of John Lonks). The MICs 
and MBCs of ciprofloxacin, trovafloxacin, penicillin 
and erythromycin, as well as penicillin and erythro- 
mycin susceptibility phenotypes are presented in Table 
1. These strains were introduced into a two-compart- 
ment artificial capillary model that simulates human 
pharmacokinetics in vitro [5]. 
The model consists of a central compartnient 
which mimics ‘serum’ concentrations and six hio- 
reactor artificial capillary chambers (Unisyn Fibertech 
Corporation, San Diego, California, USA) connected 
in series which constitute the peripheral compartment. 
The antibiotic is introduced into the central compart- 
ment a t  time zero to simulate an oral dose. At the end 
of a 60-min infusion, the concentration of the drug 
reaches a maximum analogous to the C,,, achieved 
after absorption of drug into the circulation. To further 
miniic human pharmacokinetics, the concentration of 
drug decreases as sterile, antibiotic-free Mueller- 
Hinton broth is infused at a rate equal to the drug 
elimination rate (half-life). The changing concentra- 
tions of antibiotic are pumped to the six hioreactors of 
the peripheral Compartment, where they diffuse 
through the capillary walls to contact the bacteria. 
Ciprofloxacin was administered to mimic 750 mg every 
12 h, and trovafloxacin dosing simulated 300 nig every 
34 h. Three strains were also studied at a trovafloxacin 
dose of 200 mg every 24 h. 
Log-phase bacteria were used a t  initial inocula 
that ranged from 2 x 10’ to 5 x 10h colony-forming 
units/mL. The peripheral compartments were sampled 
every 3 h for 24 h (except for hour 16 or 18), yielding 
a mixture of bacteria and antibiotic, the relative 
proportions of which are constantly changing. The 
central compartment was sampled hourly for the first 
8 h and then subsequently every 2 h. The central 
compartment remains sterile during these experiments. 
Bacterial counts on samples from the peripheral 
compartment were determined by filtration-plating. 
The concentrations of both antibiotics in the two 
compartments were determined by bioassay [6]. For 
ciprofloxacin, well-plates seeded with Eschevichicz coli 
ATCC 25922 were used, and plates used to determine 
trovafloxacin concentrations contained Bacillus subtilis 
spores. Pharmacokinetic parameters were calculated 
using trapezoidal and regression methods (Holford 
NHG, MKMODEL, Version 3,  Biosoft, 1990). 
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Figure 1 Time course of central compartment antibiotic 
concentrations: (a) ciprofloxacin simulated at 750 nig every 
12 h; (b) trovafloxacin simulated at 300 mg ( W )  and 
200 mg (+) every 2 1  h. 
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Figure 2 Mean of duplicate bacterial counts for six strains of Streptococcus pneurnoniae exposed to simulated trovafloxacin 
dosing at 300 mg every 24 h in an in vitro dynamic model. 
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Figure 3 Mean of duplicate bacterial counts for the same six strains of Streptococcus pneurnoniae as in Figure 2 exposed to 
simulated ciprofloxacin dosing at 750 mg every 12 h in an in vitro dynamic model. 
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Figure 4 Mean of duplicate bacterial counts for three 
strains of Stvcptococcirs pncumoniae exposed to simulated 
trovafloxacin dosing at 200 ing every 2.1 h (a) and to 
ciprofloxacin dosing at 7.50 rng every 12 h (b). 
RESULTS 
The time courses of central compartment concen- 
trations of ciprofloxacin and trovafloxacin are shown in 
Figure 1, and the time courses of bacterial killing are 
shown in Figures 2-4. Bacterial growth in the absence 
of antibiotic showed an increase from 5.81-6.46 log 
CFU at 0 h to 8.3-9.63 log CFU at 8 h. 
As noted above, Streptococctrs prieurnoniac 1 8( )32 was 
not susceptible to ciprofloxacin; its MIC of 32 mg/L 
was considerably higher than the MIC<,(, of 0.25 mg/L 
for trovafloxacin (MIC 1 mg/L). Neither antibiotic 
effectively eradicated this strain. Trovafloxacin at  
300 mg every 34 h killed all five other strains by 6 h, 
independent of penicillin susceptibility, and regrowth 
did not occur (Figure 2). Ciprofloxacin at  750 mg every 
12 h also killed three strains within 12 h and reduced 
the inoculum of the other two by 3-4 logs (Figure 3). 
When tested at a trovafloxacin dose of 200 mg every 
2-1 h, the three strains behaved similarly to both this 
drug and ciprofloxacin, although strain 6691 was not 
completely killed by the latter drug (Figure 4). 
DISCUSSION 
The new fluoronaphthyridone trovafloxacin demon- 
strated more coniplete eradication of penicillin- 
resistant and -sensitive strains of Streptoroccur pneurnorziae 
tested in the pharmacokinetic model compared to the 
older fluoroquinolone ciprofloxacin. Trovafloxacin 
killed five of the six pneumococcal strains in 4 h at a 
simulated oral dose of 300 mg every 24 h. Cipro- 
floxacin at the higher than usual dose of 750 mg every 
12 h eradicated three strains by 24 h and reduced the 
inoculum of two other strains by 3-5 logs. However, 
trovafloxacin and ciprofloxacin at 750 mg every 12 h 
performed similarly against three strains tested at the 
lower trovafloxacin dose of 2OOmg every 34 h. 
Incidentally, this is the dose that is recommended 
clinically. It is unlikely that antibiotic carryover could 
explain these data, as the concentrations of drugs 
exposed to bacteria are reduced by dilution in the 
central Compartment and back-diffusion from the 
peripheral compartment in the model. Also, niultiple 
serial dilutions and filterings are performed on samples 
withdrawn from the peripheral chamber. In other 
experiments in progress, bacteria exposed to single 
simulated doses in the in vitro model are capable of 
regrowth if the observation period is longer than 24 h. 
Trovafloxacin is known to be more active in vitro 
against penicillin-resistant pneuniococci than macro- 
lides, p-lactmi antibiotics and trimethoprini- 
sulfamethoxazole 131. Although ciprofloxacin was not 
initially approved for the treatment of pneuniococcal 
infections, it has recently been approved for use in the 
treatment of respiratory infections. The data presented 
here suggest that the higher dose of ciprofloxacin 
provides similar results to a 200-nig simulated dose of 
trovafloxacin in the in vitro dynamic model used. The 
clinical activity of these drugs should be compared in 
clinical studies with appropriate doses. 
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